A biomarker for CDK4/6 inhibitors
April 2019

LA JOLLA, Calif.—ActivX Biosciences Inc., a wholly owned subsidiary of Kyorin Pharmaceutical Co. Ltd., announced last month that some of its research had been published in Molecular Cancer Therapeutics regarding the molecular mechanism that determines an individual’s sensitivity or resistance to CDK4/6 inhibitors. The work looked at CDK4/6 inhibitors palbociclib (Ibrance), ribociclib (Kisqali) and abemaciclib (Verzenio), all of which are approved to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Researchers from ActivX and Vall d’Hebron Institute of Oncology applied the former’s KiNativ platform to demonstrate that high levels of p16/CDKN2A, an endogenous regulator of CDK4/6, could function as a biomarker to screen out patients unlikely to respond to CDK4/6 inhibitors.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.